drugset
Drugs / PF-06835919
last change Nov 2023 re-read 9 days ago

PF-06835919

also known as 2-[(1R,5S,6R)-3-{2-[(2S)-2-METHYLAZETIDIN-1-YL]-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL}-3-AZABICYCLO[3.1.0]HEXAN-6-YL]ACETIC ACID · KETOHEXOKINASE INHIBITOR 1

Small molecule targets KHK via inhibition

Developed for
NAFLD1 · fatty liver disease · metabolic dysfunction-associated steatohepatitis
Investigated by
Pfizer · Maastricht University Medical Center

Trials 8

today NCT05463575 · Ph 2 NCT04427917 · Ph 1 NCT04193436 · Ph 1 NCT03969719 · Ph 2 NCT03916406 · Ph 1 NCT03256526 · Ph 2 NCT03031119 · Ph 1 NCT02974374 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT04427917 Nov 2020 → Mar 2021 — Pfizer Completed No outcome recorded
Phase 1 NCT04193436 Jan 2020 → Jul 2021 — Pfizer Completed No outcome recorded
Phase 1 NCT03916406 Apr → Jun 2019 — Pfizer Completed No outcome recorded
Phase 1 NCT03031119 Jan → Jul 2017 — Pfizer Completed No outcome recorded
Phase 1 NCT02974374 Oct 2016 → Jan 2017 NAFLD1 Pfizer Completed No outcome recorded
Phase 23 trials · 1 met primary
Phase 2 NCT05463575 Oct 2022 → Nov 2023 fatty liver disease Maastricht University Medical Center Completed No outcome recorded
Phase 2 NCT03969719 Jul 2019 → Mar 2021 metabolic dysfunction-associated steatohepatitis Pfizer Completed Mixed
Phase 2 NCT03256526 Sep 2017 → Mar 2018 NAFLD1 Pfizer Completed Met primary

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as PF-06835919 “PF-06835919 is well-tolerated and has not been associated with major side-effects.” NCT05463575 ↗
7

NCT02974374 ↗

NCT03256526 ↗

NCT04427917 ↗

NCT03969719 ↗

NCT03916406 ↗

NCT03031119 ↗

NCT04193436 ↗
Known as 2-[(1R,5S,6R)-3-{2-[(2S)-2-METHYLAZETIDIN-1-YL]-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL}-3-AZABICYCLO[3.1.0]HEXAN-6-YL]ACETIC ACID ChEMBL registry synonym — accepted as the source's own label CHEMBL4549658 ↗
Known as KETOHEXOKINASE INHIBITOR 1 ChEMBL registry synonym — accepted as the source's own label CHEMBL4549658 ↗
Action Inhibit “the reversible KHK inhibitor PF-06835919” PMID 35590219 ↗ Apr 2021
Modality Small molecule — CHEMBL4549658 ↗
Route Oral “Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects” NCT02974374 ↗
Target KHK “the reversible KHK inhibitor PF-06835919” PMID 35590219 ↗ Apr 2021